Compare · FTRE vs ILMN
FTRE vs ILMN
Side-by-side comparison of Fortrea Holdings Inc. (FTRE) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FTRE and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.78B, about 17.1x FTRE ($1.68B).
- Over the past year, FTRE is up 253.1% and ILMN is up 92.0% - FTRE leads by 161.0 points.
- ILMN has been more active in the news (10 items in the past 4 weeks vs 3 for FTRE).
- Both have 25 recent analyst ratings on file.
- Company
- Fortrea Holdings Inc.
- Illumina Inc.
- Price
- $17.73-0.20%
- $189.36-0.45%
- Market cap
- $1.68B
- $28.78B
- 1M return
- +8.51%
- +16.58%
- 1Y return
- +253.09%
- +92.05%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 3
- 10
- Recent ratings
- 25
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest FTRE
- Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
- Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Fortrea Names Jason Knoblauch as Chief Financial Officer
- Director Sanders Machelle converted options into 38,817 shares, increasing direct ownership by 533% to 46,099 units (SEC Form 4)
- Director Smith David Ross converted options into 38,817 shares and covered exercise/tax liability with 18,244 shares, increasing direct ownership by 216% to 30,117 units (SEC Form 4) (tax liability)
- Director Pesicka Edward A converted options into 38,817 shares, increasing direct ownership by 285% to 52,453 units (SEC Form 4)
- SEC Form 4 filed by Director Neupert Peter M
- Chief Operating Officer Morais Mark A. sold $78,617 worth of shares (4,674 units at $16.82), decreasing direct ownership by 6% to 71,365 units (SEC Form 4)
- Director Ray Amrit converted options into 38,817 shares, increasing direct ownership by 285% to 52,453 units (SEC Form 4)
- SEC Form 4 filed by Director Sharbaugh William J
Latest ILMN
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors